Article Details
Retrieved on: 2024-09-25 17:51:55
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Goldman Sachs notes that although the Phase 3 efficacy data for rocatinlimab is less compelling compared to Dupixent, the analyst still sees strong ...
Article found on: finance.yahoo.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here